Inflammatory signature in amyotrophic lateral sclerosis predicting disease progression.
Amyotrophic lateral sclerosis (ALS)
Cerebrospinal fluid (CSF)
Cytokines
Disease progression
Neuroinflammation
Neutrophil-to-lymphocytes ratio (NLR)
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 08 2024
27 08 2024
Historique:
received:
31
01
2024
accepted:
09
07
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
Experimental studies identified a role of neuroinflammation in the pathogenesis of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). However, the role of inflammatory molecules as diagnostic and prognostic biomarkers in patients with ALS is unclear. In this cross-sectional study, the cerebrospinal fluid (CSF) levels of a set of inflammatory cytokines and chemokines were analyzed in 56 newly diagnosed ALS patients and in 47 age- and sex-matched control patients without inflammatory or degenerative neurological disorders. The molecules analyzed included: interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-17, granulocyte colony stimulating factor (GCSF), macrophage inflammatory protein (MIP)-1a, MIP-1b, tumor necrosis factors (TNF), eotaxin. Principal component analysis (PCA) was used to explore possible associations between CSF molecules and ALS diagnosis. In addition, we analyzed the association between CSF cytokine profiles and clinical characteristics, including the disease progression rate score, and peripheral inflammation assessed using the Neutrophil-to-lymphocyte ratio (NLR). PCA identified six principal components (PCs) explaining 70.67% of the total variance in the CSF cytokine set. The principal component (PC1) explained 26.8% of variance and showed a positive load with CSF levels of IL-9, IL-4, GCSF, IL-7, IL-17, IL-13, IL-6, IL-1β, TNF, and IL-2. Logistic regression showed a significant association between PC1 and ALS diagnosis. In addition, in ALS patients, the same component was significantly associated with higher disease progression rate score and positively correlated with NLR. CSF inflammatory activation in present in ALS at the time of diagnosis and may characterize patients at higher risk for disease progression.
Identifiants
pubmed: 39187524
doi: 10.1038/s41598-024-67165-9
pii: 10.1038/s41598-024-67165-9
doi:
Substances chimiques
Cytokines
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19796Informations de copyright
© 2024. The Author(s).
Références
Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400, 1363–1380. https://doi.org/10.1016/S0140-6736(22)01272-7 (2022).
doi: 10.1016/S0140-6736(22)01272-7
pubmed: 36116464
pmcid: 10089700
Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 3, 17071. https://doi.org/10.1038/nrdp.2017.71 (2017).
doi: 10.1038/nrdp.2017.71
pubmed: 28980624
McCauley, M. E. & Baloh, R. H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715–730. https://doi.org/10.1007/s00401-018-1933-9 (2019).
doi: 10.1007/s00401-018-1933-9
pubmed: 30465257
Graves, M. C. et al. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 5, 213–219. https://doi.org/10.1080/14660820410020286 (2004).
doi: 10.1080/14660820410020286
pubmed: 15799549
Prinz, M. & Priller, J. The role of peripheral immune cells in the CNS in steady state and disease. Nat. Neurosci. 20, 136–144. https://doi.org/10.1038/nn.4475 (2017).
doi: 10.1038/nn.4475
pubmed: 28092660
Beers, D. R. & Appel, S. H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 18, 211–220. https://doi.org/10.1016/S1474-4422(18)30394-6 (2019).
doi: 10.1016/S1474-4422(18)30394-6
pubmed: 30663610
Moreno-Martinez, L., Calvo, A. C., Muñoz, M. J. & Osta, R. Are circulating cytokines reliable biomarkers for amyotrophic lateral sclerosis?. Int. J. Mol. Sci. 20, 2759. https://doi.org/10.3390/ijms20112759 (2019).
doi: 10.3390/ijms20112759
pubmed: 31195629
pmcid: 6600567
Mitchell, R. M. et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72, 14–19. https://doi.org/10.1212/01.wnl.0000333251.36681.a5 (2009).
doi: 10.1212/01.wnl.0000333251.36681.a5
pubmed: 18987350
Kuhle, J. et al. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16, 771–774. https://doi.org/10.1111/j.1468-1331.2009.02560.x (2009).
doi: 10.1111/j.1468-1331.2009.02560.x
pubmed: 19236470
Tateishi, T. et al. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J. Neuroimmunol. 222, 76–81. https://doi.org/10.1016/j.jneuroim.2010.03.004 (2010).
doi: 10.1016/j.jneuroim.2010.03.004
pubmed: 20381883
Ehrhart, J. et al. Humoral factors in ALS patients during disease progression. J. Neuroinflamm. 12, 127. https://doi.org/10.1186/s12974-015-0350-4 (2015).
doi: 10.1186/s12974-015-0350-4
Lu, C. H. et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 3, e244. https://doi.org/10.1212/NXI.0000000000000244 (2016).
doi: 10.1212/NXI.0000000000000244
pubmed: 27308305
pmcid: 4897985
Guo, J., Yang, X., Gao, L. & Zang, D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 7, e00637. https://doi.org/10.1002/brb3.637 (2017).
doi: 10.1002/brb3.637
pubmed: 28293476
pmcid: 5346523
Hu, Y. et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci. Rep. 7, 9094. https://doi.org/10.1038/s41598-017-09097-1 (2017).
doi: 10.1038/s41598-017-09097-1
pubmed: 28831083
pmcid: 5567306
Chen, X., Hu, Y., Cao, Z., Liu, Q. & Cheng, Y. Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis: A systematic review and meta-analysis. Front. Immunol. 9, 2122. https://doi.org/10.3389/fimmu.2018.02122 (2018).
doi: 10.3389/fimmu.2018.02122
pubmed: 30283455
pmcid: 6156158
Olesen, M. N. et al. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 7, e697. https://doi.org/10.1212/NXI.0000000000000697 (2020).
doi: 10.1212/NXI.0000000000000697
pubmed: 32123048
pmcid: 7136052
Leone, M. A. et al. Neutrophils-to-lymphocyte ratio is associated with progression and overall survival in amyotrophic lateral sclerosis. Biomedicines 10, 354. https://doi.org/10.3390/biomedicines10020354 (2022).
doi: 10.3390/biomedicines10020354
pubmed: 35203564
pmcid: 8962424
Gille, B. et al. Inflammatory markers in cerebrospinal fluid: Independent prognostic biomarkers in amyotrophic lateral sclerosis?. J. Neurol. Neurosurg. Psychiatry 90, 1338–1346. https://doi.org/10.1136/jnnp-2018-319586 (2019).
doi: 10.1136/jnnp-2018-319586
pubmed: 31175169
Brooks, B. R., Miller, R. G., Swash, M., El Munsat, T. L., World Federation of Neurology Research Group on Motor Neuron Diseases. Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 293–299. https://doi.org/10.1080/146608200300079536 (2000).
doi: 10.1080/146608200300079536
pubmed: 11464847
Cedarbaum, J. M. et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J. Neurol. Sci. 169, 13–21. https://doi.org/10.1016/s0022-510x(99)00210-5 (1999).
doi: 10.1016/s0022-510x(99)00210-5
pubmed: 10540002
Labra, J., Menon, P., Byth, K., Morrison, S. & Vucic, S. Rate of disease progression: A prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry 87, 628–632. https://doi.org/10.1136/jnnp-2015-310998 (2016).
doi: 10.1136/jnnp-2015-310998
pubmed: 26152368
Furukawa, T. et al. CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol. Neuroimmunol. Neuroinflamm. 2, e138. https://doi.org/10.1212/NXI.0000000000000138 (2015).
doi: 10.1212/NXI.0000000000000138
pubmed: 26280014
pmcid: 4529282
Zhang, W., Xiao, D., Mao, Q. & Xia, H. Role of neuroinflammation in neurodegeneration development. Signal Trans. Target. Ther. 8, 267. https://doi.org/10.1038/s41392-023-01486-5 (2023).
doi: 10.1038/s41392-023-01486-5
Dahlke, C. et al. Inflammation and neuronal death in the motor cortex of the wobbler mouse, an ALS animal model. J. Neuroinflamm. 12, 215. https://doi.org/10.1186/s12974-015-0435-0 (2015).
doi: 10.1186/s12974-015-0435-0
Obrador, E. et al. Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis. Antioxidants 9, 901. https://doi.org/10.3390/antiox9090901 (2020).
doi: 10.3390/antiox9090901
pubmed: 32971909
pmcid: 7555310
Centonze, D. et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29, 3442–3452. https://doi.org/10.1523/JNEUROSCI.5804-08.2009 (2009).
doi: 10.1523/JNEUROSCI.5804-08.2009
pubmed: 19295150
pmcid: 6665268
Mandolesi, G. et al. Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J. Neurosci. 33, 12105–12121. https://doi.org/10.1523/JNEUROSCI.5369-12.2013 (2013).
doi: 10.1523/JNEUROSCI.5369-12.2013
pubmed: 23864696
pmcid: 6794065
Stampanoni Bassi, M. et al. Interleukin-6 disrupts synaptic plasticity and impairs tissue damage compensation in multiple sclerosis. Neurorehabil. Neural Repair 33, 825–835. https://doi.org/10.1177/1545968319868713 (2019).
doi: 10.1177/1545968319868713
pubmed: 31431121
Taipa, R. et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer’s disease and their correlation with cognitive decline. Neurobiol. Aging 76, 125–132. https://doi.org/10.1016/j.neurobiolaging.2018.12.019 (2019).
doi: 10.1016/j.neurobiolaging.2018.12.019
pubmed: 30711675
Shi, N. et al. Increased IL-13-producing T cells in ALS: Positive correlations with disease severity and progression rate. J. Neuroimmunol. 182, 232–235. https://doi.org/10.1016/j.jneuroim.2006.10.001 (2007).
doi: 10.1016/j.jneuroim.2006.10.001
pubmed: 17097743
Tanaka, T. et al. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspect. Biol. 6, a016295. https://doi.org/10.1101/cshperspect.a016295 (2014).
doi: 10.1101/cshperspect.a016295
Maurer, M. & von Stebut, E. Macrophage inflammatory protein-1. Int. J. Biochem. Cell Biol. 36, 1882–1886. https://doi.org/10.1016/j.biocel.2003.10.019 (2004).
doi: 10.1016/j.biocel.2003.10.019
pubmed: 15203102
Stampanoni Bassi, M. et al. Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. Ther. Adv. Neurol. Disord. 13, 1756286420970833. https://doi.org/10.1177/1756286420970833 (2020).
doi: 10.1177/1756286420970833
pubmed: 33343708
pmcid: 7727083
Milovanovic, J. et al. Interleukin-17 in chronic inflammatory neurological diseases. Front. Immunol. 11, 947. https://doi.org/10.3389/fimmu.2020.00947 (2020).
doi: 10.3389/fimmu.2020.00947
pubmed: 32582147
pmcid: 7283538
Capogna, E. et al. Associations of neuroinflammatory IL-6 and IL-8 with brain atrophy, memory decline, and core AD biomarkers: In cognitively unimpaired older adults. Brain Behav. Immun. 113, 56–65. https://doi.org/10.1016/j.bbi.2023.06.027 (2023).
doi: 10.1016/j.bbi.2023.06.027
pubmed: 37400002
Kokubo, K. et al. Conventional and pathogenic Th2 cells in inflammation, tissue repair, and fibrosis. Front. Immunol. 13, 945063. https://doi.org/10.3389/fimmu.2022.945063 (2022).
doi: 10.3389/fimmu.2022.945063
pubmed: 36016937
pmcid: 9395650
Elyaman, W. & Khoury, S. J. Th9 cells in the pathogenesis of EAE and multiple sclerosis. Semin. Immunopathol. 39, 79–87. https://doi.org/10.1007/s00281-016-0604-y (2017).
doi: 10.1007/s00281-016-0604-y
pubmed: 27844107
Cottler-Fox, M. H. et al. Stem cell mobilization. in Hematology. American Society of Hematology. Education Program, 419–437 (2003). https://doi.org/10.1182/asheducation-2003.1.419
Pitzer, C. et al. The hematopoietic factor granulocyte-colony stimulating factor improves outcome in experimental spinal cord injury. J. Neurochem. 113, 930–942. https://doi.org/10.1111/j.1471-4159.2010.06659.x (2010).
doi: 10.1111/j.1471-4159.2010.06659.x
pubmed: 20202082
Nishio, Y. et al. Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice. J. Neuropathol. Exp. Neurol. 66, 724–731. https://doi.org/10.1097/nen.0b013e3181257176 (2007).
doi: 10.1097/nen.0b013e3181257176
pubmed: 17882016
Cashman, N. et al. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 37, 620–625. https://doi.org/10.1002/mus.20951 (2008).
doi: 10.1002/mus.20951
pubmed: 18335482
Zhang, Y. et al. Preliminary investigation of effect of granulocyte colony stimulating factor on amyotrophic lateral sclerosis. Amyotrop. Lateral Scler. 10, 430–431. https://doi.org/10.3109/17482960802588059 (2009).
doi: 10.3109/17482960802588059
Nefussy, B. et al. Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study. Amyotrop. Lateral Scler. 11, 187–193. https://doi.org/10.3109/17482960902933809 (2010).
doi: 10.3109/17482960902933809
Chiò, A. et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle Nerve 43, 189–195. https://doi.org/10.1002/mus.21851 (2011).
doi: 10.1002/mus.21851
pubmed: 21254083
Johannesen, S. et al. Biomarker supervised G-CSF (filgrastim) response in ALS patients. Front. Neurol. 9, 971. https://doi.org/10.3389/fneur.2018.00971 (2018).
doi: 10.3389/fneur.2018.00971
pubmed: 30534107
pmcid: 6275232
Lopez-Lopez, A. et al. CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS ONE 9, e96528. https://doi.org/10.1371/journal.pone.0096528 (2014).
doi: 10.1371/journal.pone.0096528
pubmed: 24806473
pmcid: 4013026
Wosiski-Kuhn, M. et al. IL6 receptor
doi: 10.1212/NXI.0000000000000631
pubmed: 31611269
pmcid: 6865852
Béland, L. C. et al. Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2, 124. https://doi.org/10.1093/braincomms/fcaa124 (2020).
doi: 10.1093/braincomms/fcaa124
Grillo, P. et al. Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson Disease patients. Parkinsonism Relat. Disord. 112, 105480. https://doi.org/10.1016/j.parkreldis.2023.105480 (2023).
doi: 10.1016/j.parkreldis.2023.105480
pubmed: 37290213
Mehta, N. H. et al. Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline. Sci. Rep. 13, 8847. https://doi.org/10.1038/s41598-023-34012-2 (2023).
doi: 10.1038/s41598-023-34012-2
pubmed: 37258519
pmcid: 10232445